Covid-19 reagents for the alinity m
Ended Awarded Last action
- Contract number
- 36C25922N0171
- Awardee
-
Abbott Molecular Inc. UEI NK5QDVJBHMN7 Part of Abbott Laboratories
- Awarding agency
-
Veterans Integrated Service Network 19
Veterans Health Administration, Department of Veterans Affairs
- Obligated
- $214,528
Award facts
- Contract value 8% obligated
-
- $214,528.00 Current, with exercised options
- $2,697,423.40 Potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- Contracting staff
- NAICS code
- 325413 In-Vitro Diagnostic Substance Manufacturing
- Competition
- Full and Open Competition Multiple Award, Fair Opportunity
- Pricing
- Firm Fixed Price
- Place of performance
- Aurora, CO 80045, USA
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Funding Only Action | -$83,932 | |
| Original award | $298,460 |
About this award
Abbott Molecular Inc., a subsidiary of Abbott Laboratories, was awarded a Blanket Purchase Agreement call valued at $2.7 million on January 11, 2022, for COVID-19 reagents supporting the Alinity M molecular diagnostic analyzer platform. The contract, funded by Veterans Integrated Service Network 19 (a civilian entity within the Department of Veterans Affairs), was performed at Abbott Molecular's Aurora, Colorado facility with a completion date of November 30, 2022. As a firm fixed-price delivery order issued under the GSA Schedule In-Vitro Diagnostics, Reagents, Test (FSS-65-VII), this award represents a task order against an existing BPA vehicle, enabling the VA to rapidly procure critical pandemic response testing supplies. The contract carries no small business set-aside designation, reflecting Abbott Molecular's status as a large, established medical technology corporation with extensive federal contracting experience.
This award represents Abbott Molecular's continued strategic role in supporting the federal government's diagnostic testing infrastructure during the COVID-19 pandemic response. The company maintains multiple Blanket Purchase Agreements across numerous Veterans Integrated Service Networks and federal agencies, with cumulative IDV values exceeding $12 million for Alinity M reagents and related consumables. The Alinity M platform has become a standardized molecular diagnostic system across VA healthcare networks for infectious disease screening, including COVID-19, HIV, and hepatitis C testing, making reliable reagent supply chains essential to veterans' healthcare delivery and federal pandemic preparedness.
Quick answers
Who was awarded contract 36C25922N0171?
36C25922N0171 was awarded to Abbott Molecular Inc. by Veterans Integrated Service Network 19 (Veterans Health Administration) on January 11, 2022.
How much is contract 36C25922N0171 worth?
The government has obligated $214,528 on 36C25922N0171. Its potential value, with all options, is $2,697,423.
Is contract 36C25922N0171 an order under another contract?
Yes. 36C25922N0171 is a BPA call under V797D40222-36C25922A0005, a blanket purchase agreement, on Invitro Diagnostics, Reagents, Test (FSS-65-VII).
Was contract 36C25922N0171 competed?
The extent of competition for 36C25922N0171 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award